Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status
2016
Background
Anagrelide represents a treatment option for essential thrombocythemia, although its place in therapy remains controversial.
Aim
To assess the impact of mutational status in response rates and development of adverse events during long-term use of anagrelide.
Methods
We retrospectively evaluated 67 patients with essential thrombocythemia treated with anagrelide during 68 (4–176) months.
Results
Mutational frequencies were 46.3%, 28.3%, and 1.5% for JAK2V617F, CALR and MPL mutations. Anagrelide yielded a high rate of hematologic responses, which were complete in 49.25% and partial in 46.25%, without differences among molecular subsets. The rate of thrombosis during treatment was one per 100 patient-years, without excess bleeding. Anemia was the major adverse event, 30.3% at 5-yr follow-up, being more frequent in CALR + (P 60 months were at higher risk, OR (95% CI) 9.32 (1.1–78.5), P < 0.01, indicating the need for bone marrow monitoring during prolonged treatment.
Conclusion
Although CALR + patients were at higher risk of developing anemia, anagrelide proved effective among all molecular subsets, indicating that mutational status does not seem to represent a major determinant of choice of cytoreductive treatment among essential thrombocythemia therapies.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
34
References
13
Citations
NaN
KQI